VCM
PRCT icon

Vigilant Capital Management’s Procept Biorobotics PRCT Stock Holding History

Vigilant Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$4K Hold
100
– – ﹤0.01% 433
2023
Q1 		$3K Hold
100
– – ﹤0.01% 421
2022
Q4 		$4K Buy
+100
New +$4.29K ﹤0.01% 460

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Vigilant Capital Management's PRCT Position: Q2 2023 in Review

Vigilant Capital Management held its Procept Biorobotics (PRCT) position steady in Q2 2023 at 100 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #433.

Vigilant Capital Management first reported a position in PRCT in Q4 2022 and has held it in 3 quarters since. 120 funds tracked by Wall St. Rank hold PRCT as of Q2 2023.

  • Vigilant Capital Management held 100 shares of Procept Biorobotics worth $4K as of Q2 2023.
  • Vigilant Capital Management left its Procept Biorobotics share count unchanged in Q2 2023.
  • Procept Biorobotics made up ﹤0.01% of Vigilant Capital Management's portfolio in Q2 2023, its #433 holding.
  • Vigilant Capital Management first reported a position in Procept Biorobotics in Q4 2022 and has held it in 3 quarters since.
  • 120 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2023.

Based on Vigilant Capital Management's 13F filing for Q2 2023, filed 8 Aug 2023.